Since the first cell therapeutic study to repair articular cartilage defects in the knee in 1994, several 
 [1] [2] [3] 
. This very limited healing capacity of cartilage is partially due to its avascularity. Therefore, the classical wound healing response, where a set of complex biochemical events takes place to repair the damage, does not occur in cartilage. When cartilage is wounded, the tissue at the wound edge is damaged and cells die, resulting in debris similar to wounds in other tissues. However, this damaged and avital cartilage tissue will not be removed. Wound healing is prevented by avascularity in combination with an impaired migration capacity of cartilage cells through the dense extracellular matrix
. In fullthickness ICRS (International Cartilage Repair Society) grade IV (superficial osteochondral) defects, bleeding from the underlying bone marrow will, to some extent, trigger a natural wound healing reaction. Non-vital tissue will be partially resorbed and cells are attracted to the wound area, with proliferation, differentiation and new matrix production [3] . However, the resulting fibrocartilaginous repair tissue is of inferior quality, rather classified as scar tissue, a fact which is associated with an increased risk for gradual development of secondary osteoarthritis. Besides surgically punching or drilling holes through the subchondral plate, called marrow stimulation techniques, there was no other regenerative treatment option for symptomatic joint surface defects available until 1994 when the first cell therapeutic approach for cartilage repair, autologous chondrocyte implantation (ACI), found its way into the clinic [6] .
Autologous chondrocyte implantation
The original ACI procedure involves the isolation of chondrocytes from a cartilage biopsy harvested during an arthroscopic procedure from a less load-bearing area of the knee with the defect. After expansion in monolayer culture, the cells in solution are shipped back to the orthopaedic surgeon. The cell solution is injected during a surgical procedure under a flap of periosteum harvested from the tibia that has been fixed with sutures, fibrin glue (or both) to the edges of the cartilage lesions.
Since the first report by Brittberg et al. on the first 23 patients in 1994 [6] , ACI has been performed in more than 30 [7] .
Reports on results with ACI from other centres [8] [9] [10] 
show similar figures with a high degree of success, however the evidence level of these reports is II or lower. In order to properly position this new treatment in an algorithm, and to establish its relevance for daily clinical practice, ACI needs to be evaluated in direct comparison to other cartilage repair techniques in prospective randomized trials [11]. The findings described above are related to what one defines as the first generation of ACI with cells in suspension covered with a periosteal flap. In a so-called second generation of an ACI procedure, the periosteum has been replaced with a collagen membrane. This approach was mainly developed to improve the surgical and patient friendliness, but it is still unclear how far this is affecting outcome. The third generation of cartilage repair products involves so-called combination products (CP) being either cells grown on a carrier membrane such as matrix-induced autologous chondrocyte implantation (MACI) or cells seeded and grown in a scaffold such as hyaluronic acid (Figure 1) or collagen.

Combination products
Behrens et al. [12] [63] . Zuk et al. [63, 64] Cells from the synovium have chondrogenic potential [66] . The study by Sakaguchi et al. [67] showed that human synovialderived cells had greater chondrogenic potential than BMSCs, ADSCs, periosteal-or muscle-derived cells from the same patients, and a follow-up study showed that synovial-derived cells produced consistently larger cartilage aggregates than BMSCs from the same patients [68] . The synovial fluid of arthritic knees of patients has been reported to contain MSCs [69] [71] , umbilical cord [72] and tendon [73] . [79] . This breakthrough technique was further improved [80] [81] [82] [88] [89] [90] and synergistic effects of BMPs and TGF-␤ on chondrogenic differentiation were also reported [88] . TGF-␤ has also been used together with FGF-2 [91] , growth and differentiation factor-5 [92] [90] and in chondrocytes cultured in alginate [120] [121] [122] [123] [124] . Overexpression of BMP-2 in vivo induces matrix turnover and thereby contributes to the intrinsic repair capacity of damaged cartilage [125] . In addition to its strong pro-anabolic activity, BMP-7 has very prominent anti-catabolic properties [123] . Animal studies have demonstrated that this factor has the ability to repair cartilage in vivo in various models of articular cartilage degradation (see [107] for review). When BMP-7 and BMP-2 are combined in a chondrocyte alginate culture, they work synergistically [122] . [127] [128] [129] [130] [131] .
Choice of cell types
Hunziker and colleagues [132] reported that during normal development articular cartilage is physiologically reorganized by a process of tissue resorption and neoformation, rather than by internal remodelling [132] [133] . A poly lactic-co-glycolic acid (PGLA) microsphere system also seemed to be a functional device for the delivery of growth factors such as BMP-7 during the cultivation of articular chondrocytes [134] . Also systems have been designed for the controlled release of two factors [135, 136] .
We [137] . [141, 142] .
Interference of inflammation with cartilage repair
In healthy joints, homeostasis exists. When this stable equilibrium of cartilage, bone, ligaments and synovium in a well-functioning biomechanical system is disturbed, a myriad of inflammatory factors and cellular responses come into play. The harmful effects on cartilage repair of biomechanical factors, such as malalignment, lack of menisci and ligamentous insufficiency, have been recognized and correction of these conditions at the time of cartilage repair procedure is recommended. Much less attention has been paid to inflammation and its eventual harmful effects on the repair process. Inflammation in the medical jargon is often considered as the source of evil, leading to classical symptoms and signs of inflammation, rubor, tumour, dolour, calor and functio laesa. Inflammatory pain and autoimmune inflammation in the medical setting often require treatment with non-steroidal, steroidal and biological anti-inflammatory drugs. In contrast to this pragmatic medical view, inflammation can be more broadly considered as an essential phase in tissue repair and regeneration and as an integral part of almost any host response to any noxious physical or chemical stimulus. The avascularity of the cartilage and, therefore, its inability to mount an effective inflammatory response, is considered to be the main reason for the poor repair capacity of the cartilage. This is in some cartilage repair methods overcome by drilling, abrasion or lately in particular microfracturing of the subchondral plate. These techniques result in a fibrin-rich clot of platelets (which from their alpha granules release repair factors like vascular endothelial growth factor VEGF, TGF-␤1, PDGF) and recruitment of autologous BMSC or progenitors to fill smaller Ͻ 2.5-3 cm 2 cartilage defect. In a way, marrow stimulation is based on the provocation of inflammation, which leads to mobilization of endogenous bone marrow derived MSCs. Inflammation is mediated mainly via pro-inflammatory cytokines, which may interfere with the chondrogenic and anabolic effects of growth factors used to stimulate chondrocytes and/or MSCs. Pro-inflammatory cytokines are considered to exert catabolic effects and to stimulate proteinases, which degrade extracellular cartilage matrix. Inflammation-induced functio laesa impairs cartilage tissue repair, maturation and vertical and lateral integration of the transplanted cells. Correspondingly, the most common complications of the procedure are symptomatic hypertrophy of the regenerated cartilage, disturbed fusion of the graft at the edges, partial graft failure as a result of too little cartilage production and delamination of already formed repair tissue. Several biomarkers have been described, which can be used to monitor inflammation and its consequences.
So far, ACI (ACI with a periosteal patch, ACI-P, or with a collagen cover, ACI-C) is perhaps optimally performed to repair criti-
High age and diabetes may compromise results of chondrocyte implantation and chondrogenesis also via increased production and accumulation of advanced glycation end-products (AGE). In immature cartilage under 20 years of age, the concentration of AGEs is low, but CML, CEL and pentosidine (different AGEs) increase 27-fold, 6-fold and 33-fold upon maturation, respectively [139]. This suggests that cartilage remodelling, via production of extracellular matrix, is much faster before the age of 20 years than later in life, when AGEs rapidly accumulate as a function of time. Acting through their receptor (RAGE), AGEs have immune-inflammation modulating properties but also impair expansion and trans-differentiation of MSCs to chondrocytes [140]. In the clinical setting, however, the effect of age per se on the outcome of various ACIs is not clear yet
In spite of the fact that pro-inflammatory cytokines are associated with enhanced remodelling, pro-inflammatory cytokines such as tumour necrosis factor-␣ (TNF-␣) or interleukin-1␤ (IL-1␤)
have rarely been added to the chondrogenic inductive cell culture media, mainly because it is still a challenge to produce highquality repair cartilage. Poor production of extracellular matrix and tissue destruction (catabolism) are locally present in patients even 1 year after ACI [143] . This local inflammation can be aggravated by the foreign body reaction caused by bioresorbable tissue engineering scaffolds [144] [108, 145] . [146] . It has been demonstrated that some chondrocytes used in chondrocyte transplantation undergo apoptosis [147] [152] . [158] . In GFP-transfected chondrocytes, using a retroviral vector, transgene expression and the number of implanted chondrocytes remained stable for at least 8 months in vitro and for 4 weeks in vivo [159] . In a goat model of osteoarthritis induced by ACL resection and total medial meniscectomy, MSC transduced to express GFP were found in the neomeniscal tissue, 6 weeks after intra-articular injection, but not at 20 weeks post-transplantation [160] .
Pro-inflammatory cytokines and pro-apoptotic factors may be induced by local inflammation and also by the processing and storage of the cells and tissues prior to implantation
What then are the markers that might indicate that chondrogenic differentiation of cells and cartilage repair tissue is jeopardized? Probably they overlap to a large extent with the mediators and biomarkers used to assess osteoarthritis, which is often referred to as primarily a disease of the hyaline articular cartilage. These markers not only include pro-inflammatory cytokines, proteolytic enzymes (MMPs and
Tracking of transplanted cells in vivo
Although widely used, lacZ and GFP have several important disadvantages for histological cell tracking, especially in hard tissues. LacZ is heat labile, and requires pre-embedding staining [161] . Although GFP is an excellent marker for tracking of living cells [162] , its fluorescent properties are greatly diminished during normal paraffin embedding, and sensitive detection of GFP in histological sections requires immunohistochemical detection methods [163] . Therefore, frozen sections are mostly used for histological analysis of GFP-labelled cells. However, preparation of frozen sections from hard tissues is technically extremely demanding. In addition, tissue autofluorescence is a major confounding factor in hard tissues. Recently, human placental alkaline phosphatase (hPLAP) has been described as highly suitable marker enzyme for studies involving genetically labelled cells in hard tissues [164] . This marker protein retains its enzymatic activity not only after paraffin embedding but also after a modified methylmethacrylate (MMA) embedding protocol [165] , and can be detected by histochemistry and immunohistochemistry in a very sensitive fashion [164] . The availability of a genetic marker [176, 177] , more promising results have been reported lately [178, 179] .
The proof-of-the-principle study of ACI was first discovered in New York and verified in rabbits in 1989 [180] . Brittberg and colleagues [6] [181] . Attention is now directed to expand imaging modalities such as MRI [182, 183] 
